Special Issue "Dendritic Cells and Cancer Immunotherapy"
Deadline for manuscript submissions: closed (31 May 2016).
Interests: Cancer Immunotherapy, Suppressive Tumor Microenvironment, Signaling Networks, Immunogenic Cell Death
Interests: dendritic cells, immunotherapy, tumor microenvironment, T cell polarization, immune tolerance
Dendritic cells (DCs) are a specialized population of professional antigen-presenting cells that play a crucial role in the induction of adaptive immune responses and in the maintenance of peripheral tolerance. As initiators of antigen-specific immune responses, DCs are imperative in establishing anti-tumor adaptive immune responses. This role has been exploited for therapeutic purposes in various anti-tumor vaccination strategies. Over the years, many insights into the qualities and functions of DCs have been gained. This acquired knowledge has been translated into improved DC-based vaccines through the better selection of DC subtypes for vaccine preparation and the optimization of peptide selection, loading strategies, and routes of administration. Until now, anti-tumor DC vaccines have only proven efficacious in a small population of cancer patients.
Therefore, this Special Issue on dendritic cell vaccines will focus on strategies for improving DC vaccination in combination with other therapies, such as checkpoint inhibitors, chemotherapy, or radiation therapy, that alter the tumor microenvironment. Of particular interest will be manuscripts discussing the use of DC vaccines in prophylactic or adjuvant settings through the targeting of cancer stem cells or dormant tumor cells. Manuscripts describing the accumulation DC subtypes in the tumor environment and how they might be targeted for therapeutic benefit are also welcome. This Special Issue will include original research, review articles, commentaries, and editorials discussing the use of DC vaccines in cancer immunotherapy. Topics of interest for this Special Issue include, but are not limited to, the key words listed below.
Dr. Stanleyson Hato
Dr. Ghaith Bakdash
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- DC-based anti-cancer vaccines
- DC vaccines combinded with checkpoint inhibitors
- DC vaccines combinded with chemotherapy or small molecule inhibitors
- DC maturation/activation and tumor-associated “danger” signals
- Cross-presentation of tumor antigens
- The role of DC in the induction of tumor-specific T cell responses
- The influence of tumor-derived factors on DC differentiation, maturation, activation, and function
- Immunosuppression by immature myeloid cells such as myeloid-derived suppressor cells
- Regulatory DCs and cancer